Biogen (MEX:BIIB) Institutional Ownership : 68.50% (As of Oct. 27, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Biogen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biogen's institutional ownership is 68.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biogen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biogen's Float Percentage Of Total Shares Outstanding is 88.63%.

Biogen Institutional Ownership Historical Data

The historical data trend for Biogen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Institutional Ownership Chart

Biogen Historical Data

The historical data trend for Biogen can be seen below:

	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30
Institutional Ownership	69.99	69.33	67.99	69.90	68.85	68.97	70.19	70.76	70.24	68.50

Biogen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.